HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

lobeglitazone

putative antidiabetic agent for type 2 diabetes; structure in first source
Also Known As:
CKD 501; CKD-501; CKD501
Networked: 42 relevant articles (11 outcomes, 15 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Lim, Soo: 5 articles (11/2022 - 11/2015)
2. Park, Jeong Hyun: 5 articles (01/2022 - 01/2014)
3. Chung, Choon Hee: 4 articles (11/2022 - 01/2014)
4. Choi, Dong Seop: 4 articles (10/2020 - 01/2014)
5. Kim, Doo Man: 4 articles (10/2020 - 01/2014)
6. Kim, Sin Gon: 4 articles (10/2020 - 01/2014)
7. Jang, Hak Chul: 4 articles (10/2017 - 01/2014)
8. Kim, Kyoung Min: 3 articles (01/2020 - 11/2015)
9. Yu, Kyung-Sang: 3 articles (01/2020 - 11/2011)
10. Cha, B-S: 3 articles (11/2018 - 06/2015)

Related Diseases

1. Type 2 Diabetes Mellitus (MODY)
2. Non-alcoholic Fatty Liver Disease
3. Insulin Resistance
4. Weight Gain
5. Albuminuria

Related Drugs and Biologics

1. Metformin (Glucophage)
2. Sitagliptin Phosphate (Januvia)
3. dapagliflozin
4. Pioglitazone (Actos)
5. Glucose (Dextrose)
6. Lipids
7. 2,4-thiazolidinedione (thiazolidinedione)
8. Peroxisome Proliferator-Activated Receptors (PPAR)
9. Transforming Growth Factors (Transforming Growth Factor)
10. Rosiglitazone (Avandia)

Related Therapies and Procedures

1. Therapeutics
2. Glycemic Control
3. Secondary Prevention